中国实用内科杂志2024，Vol.44Issue(2)：120-127,8.DOI:10.19538/j.nk2024020107
凝血因子FⅪ/FⅪa抑制剂:抗凝新选择?
FⅪ/FⅪa inhibitors:a new option for anticoagulation?
摘要
Abstract
Thrombosis is a significant cause of death in a variety of diseases,and anticoagulation is the main method of thrombosis inhibition.Nevertheless,currently in clinical practice,the application of most commonly used anticoagulant drugs is limited due to the risk of bleeding,particularly for patients with atrial fibrillation who require long-term anticoagulant therapy.Therefore,it is necessary to explore and develop more effective and safer anticoagulant drugs.Researchers have studied the coagulation mechanism in depth and found that F Ⅺ/F Ⅺ a inhibitors have the potential to effectively inhibit coagulation without affecting physiological hemostasis.So far,a few clinical phase Ⅱ trials involving atrial fibrillation and other diseases(such as myocardial infarction,stroke,etc.)suggest that FⅪ/FⅪa inhibitors tend to have a lower bleeding risk than direct oral anticoagulants(DOACs),which requires further studies in clinical phase Ⅲ trials to verify their effectiveness and safety.Potentially,FⅪ/FⅪa inhibitors are expected to be a new option for anticoagulation.Based on clinical practice,the author will discuss the anticoagulation mechanism,research progress and application prospects of FⅪ/FⅪa inhibitors.关键词
FⅪ/FⅪa抑制剂/抗凝治疗/心房颤动/血栓形成Key words
FⅪ/FⅪa inhibitors/anticoagulant therapy/atrial fibrillation/thrombosis分类
医药卫生引用本文复制引用
曹颖,公奥博,童瑶,胡贤进,李芳卉,曾锐..凝血因子FⅪ/FⅪa抑制剂:抗凝新选择?[J].中国实用内科杂志,2024,44(2):120-127,8.基金项目
四川省科学技术项目(2022JDRC0148) （2022JDRC0148）
